CLS Q3: An eventful quarter - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

CLS Q3: An eventful quarter - Redeye

{newsItem.title}

Redeye provides an update in relation to CLS’ Q3 2023 report. Net sales during the quarter amounted to SEK2.0m (SEK0.9m), and EBIT came in at SEK-15.6m (SEK-27.0m) compared to our sales estimate of SEK3.5m and EBIT estimate of SEK-18.7m. Overall, we are positive about the report, as CLS has been cost-effective, and the news flow has been solid. We only make some minor changes in our model, resulting in an updated fair value range (SEK0.15-0.8); however, our base case remains at SEK0.4.

Länk till analysen i sin helhet: https://www.redeye.se/research/961212/cls-q3-an-eventful-quarter?utm_source=finwire&utm_medium=RSS

Nyheter om Clinical Laserthermia

Läses av andra just nu

Om aktien Clinical Laserthermia

Senaste nytt